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TCT-150
Genetic Variants Affecting Clopidogrel Metabolism Have Minor Influence on
Platelet Reactivity After Elective Percutaneous Coronary Intervention
András Komócsi, Orsolya Rideg, Gyöngyvér Költö, András Vorobcsuk, Daniel Aradi
Heart Centre, University of Pécs, Pécs, Hungary
Background: Genetic variations affecting clopidogrel absorption and metabolism may
influence the achieved anti-platelet action. We aimed to determine the effect of various
single nucleotide polymorphisms (SNPs) on platelet reactivity in patients after elective
stent implantation.
Methods: Cytochrome 2C19 (CYP2C19) loss-of-function (*2, *3; LOF) and gain-of-
function (*17; GOF) alleles, ABCB1 (3435CÇT, 2677GÇT/A) and paraoxonase-1
(PON1; 192QÇR) SNPs were analyzed in 189 participants of a randomized, placebo-
controlled trial (NCT00638326). 12-24 hours after 600 mg clopidogrel, P2Y12 receptor
blockade was assessed with VASP phosphorylation (VASP-PRI) and 5 μM ADP-
induced residual platelet reactivity (RPR) was determined. Proportions of the
variability in platelet reactivity explained by genetic variants were analyzed by means
of R2 values in multivariate linear regression models.
Results: A significant association was found between CYP2C19 genotypes and RPR
with the lowest values in GOF homozygotes and the least effect in patients carrying
two LOF alleles. There were no significant differences in platelet reactivity indices
according to PON1 or ABCB1 genotypes. In the univariate linear regression models,
the carriage of the LOF alleles together with ABCB1 and PON1 genotypes showed
significant regression with RPR, while only LOF alleles were in significant association
with VASP-PRI. In the multivariate model, the carriage of LOF alleles proved to be
the independent determinant of RPR and VASP-PRI (unstandardized coefficient: 5.88
[CI: 1.56-10.19], p<0.01 and 8.79 [CI: 1.54-16.03], p<0.05, respectively). The
examined genetic variants explained only 8.5% and 5.7% of the variability in RPR and
VASP-PRI values, respectively.
Conclusion: CYP2C19 LOF allele status is an independent determinant of both RPR
and VASP-PRI, while CYP2C19 GOF alleles, ABCB1 and PON1 genotypes were not
significantly associated with platelet reactivity. Despite the significant association,
CYP2C19 LOF alleles explained only a minority of the variability in RPR and VASP-
PRI values.
TCT-151
Paraoxonase-1 (PON1) Activity And PON1 Polymorphisms Have No Effect On
Platelet Reactivity In Patients Treated With Clopidogrel
Jean-Pierre P Dery1, Abdelouahed Khalil3, Ugo Déry1, Mélanie Roy1, Pierluigi
Tricoci2, Richard Becker2, Stéphane Rinfret1, Éric Larose1, Gérald Barbeau1, Robert
DeLarochellière1, Josep Rodés-Cabau1, Olivier F Bertrand1
1Cardiology, Quebec Heart and Lung Institute, Quebec, Canada; 2Duke University
Clinical Research Institute, Durham, NC; 3Research Center on Aging, Sherbrooke,
Canada
Background: The contribution of paraoxonase-1 (PON1) to the bio-transformation of
clopidogrel to its active metabolite and the impact of PON1 polymorphisms on the
antiplatelet effect of clopidogrel remain controversial. We investigated the relationship
between PON1 polymorphisms, PON1 activity and on-treatment platelet reactivity in
patients treated with clopidogrel.
Methods: Following successful PCI, 207 patients treated with 75mg clopidogrel and
not on proton pump inhibitors were enrolled. On-treatment maximal platelet
aggregation (MPA) was assessed at 30 days with light transmittance aggregometry
after stimulation with 5μmol/l ADP.
Results: PON1 activity was associated with PON1 polymorphisms (QQ: 59 U/l, QR:
143 U/l, RR: 221 U/l). MPA was similar across PON1-Q192R genotypes (QQ: 38.7+/-
13.7%, QR: 39.3+/-14.6%, RR: 38.1 +/-15.5%; p=0.6) and did not differ between
quartiles of PON1 activity (37.4% vs 37.6% for lower and higher quartiles,
respectively; p=0.9). Carriers of CYP2C19*2 allele showed higher MPA when
compared to non-carriers (42.7+/-15.3% vs 37.5+/-13.5%, p=0.02). By multivariable
analysis, CYP 2C19*2 polymorphism (OR : 2.7 95%CI[1.3 - 1.5]; p<0.01), but not
PON1-192QQ polymorphism (p=0.7), nor PON1 activity (p=0.8), were associated with
high on-treatment platelet reactivity, defined by MPA >46% (5μmol/l ADP). No
interaction was found between CYP 2C19*2 and PON1-Q192R polymorphisms on
platelet reactivity. Similar results were obtained when platelet reactivity was evaluated
with VASP.
Conclusion: In patients treated with standard maintenance dose clopidogrel therapy
following PCI, PON1-Q192R polymorphisms and PON1 activity were not associated
with on-treatment platelet reactivity.
TCT-152
Pharmacodynamic Effect of Double-dose Clopidogrel versus Adding
Dipyridamole In Patients With High On-treatment Platelet Reactivity
(ACCEL-DIP) study
Yongwhi Park1, Young-Hoon Jeong2, 1, Jeong-Rang Park1, Seok-Jae Hwang1, Choong
Hwan Kwak1, Jin-Yong Hwang1
1Internal Medicine, Gyeongsang National University Hospital, Jinju, Republic of
Korea; 2Sinai Center for Thrombosis Research, Baltimore, MD
Background: High on-treatment platelet reactivity (HPR) has been associated with
ischemic event occurrence in PCI-treated patients. Antiplatelet regimens to ameliorate
ischemic risk in patients with HPR are under investigation. Dipyridamole can enhance
platelet inhibition by blocking phosphodiesterases and the active transport of adenosine
into red blood cells. However, it is not known whether adding dipyridamole can
overcome the combined risk among HPR patients during dual antiplatelet therapy with
aspirin and clopidogrel.
Methods: Preprocedural platelet measures were assessed after 600-mg loading of
clopidogrel or 75-mg maintenance of clopidogrel ( 7 days). If patients met the criteria
of HPR, they were randomly assigned to dypiridamole (Persantin®) 75mg bid plus
clopidogrel 75 mg/d (DIP group; n=29) or double-dose clopidogrel of 150 mg/d (DDC
group; n=30) on top of aspirin. Platelet reactivity (PR) was measured at preprocedure
and 14-day follow-up by light transmittance aggregometry (LTA) and VASP-PRI assay.
Primary end point was the prevalence of HPR at 14-day. HPR was defined as VASP-
PRI > 50%.
Results: Baseline platelet reactivity did not differ between the groups. After 14-day
therapy, significant reductions in platelet measures were observed in both groups
(P=0.032). At 14-day follow-up, the DIP group showed similar prevalence of HPR
compared with the DDC group (69.0% vs. 66.7%, P=0.850). The values of VASP-PRI
at 14-day follow-up were not different between the DIP vs. DDC group (60.8 ± 15.8%
vs. 56.8 ± 13.0%, P=0.287). Maximal PRs after 5 and 20 μM ADP stimuli were similar
between the DIP vs. DDC group (52.9 ± 15.4% vs. 49.1 ± 17.1%, P=0.373; 37.5 ±
14.6% vs. 36.2 ± 15.4%, P=0.726, respectively). Likewise, PR values after the addition
of 6 μg/mL collagen and 0.5 mM arachidonic acid did not differ between the groups.
Conclusion: Among PCI-treated patients with HPR, adding dipyridamole to dual
antiplatelet therapy achieves similar prevalence of HPR and platelet inhibition
compared with double-dose clopidogrel of 150 mg/d. However, both antiplatelet
regimens show the limitation to overcome the risk of HPR in these patients.
TCT-153
CYP3A4 Genetic Status May Be Associated with Increased Vulnerability to the
Adverse Effect of Calcium Channel Blockers on Clopidogrel Response
Variability
Jin Joo Park, Kyung Woo Park, Jeehoon Kang, Ki-Hyun Jeon, Si-Hyuk Kang, Hyo
Suk Ahn, Han-Mo Yang, Hae-Young Lee, Hyun-Jae Kang, Bon-Kwon Koo, Byung-
Hee Oh, Young-Bae Park, Hyo-Soo Kim
Seoul National University Hospital Cardiovascular Center, Seoul, Republic of Korea
Background: The CYP3A4 system is involved in the activation of clopidogrel.
Calcium channel blockers (CCBs) are known CYP3A4 inhibitors, but observational
studies have shown conflicting results regarding the effect of CCB administration on
clopidogrel response variability. Furthermore, reduced function genotypes may be more
vulnerable to the inhibitory effect of CCBs.
Methods: The clopidogrel on-treatment platelet reactivity (OPR) was measured and
the CYP3A4 (IVS10+12G/A) genotyped in 1555 consecutive patients who underwent
percutaneous coronary intervention at Seoul National University Hospital.
Results: The mean OPR of the entire population was 235±84 (P2Y12 Reaction Units,
PRU). Four hundred thirty-nine (28.2%) CCB users had higher OPR compared with
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